Finoriq research workspace
BIOCRYST PHARMACEUTICALS INC (BCRX) SEC Filings & Filing Highlights
BIOCRYST PHARMACEUTICALS INC markets peramivir injection, an intravenous neuraminidase inhibitor. Review BCRX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
- Company
- BIOCRYST PHARMACEUTICALS INC (BCRX)
- Ticker
- BCRX
- Market Cap
- $2.3B
- Latest Price
- $9.205
- Industry
- Biotech & Pharma
BIOCRYST PHARMACEUTICALS INC (BCRX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for BIOCRYST PHARMACEUTICALS INC (BCRX).
| Event | Form | Date |
|---|---|---|
| On June 29, 2026, the Company issued a press release announcing the Plan and other business upd...On June 29, 2026, the Company issued a press release announcing the Plan and other business updates, including with respect to our pipeline... | 8-K7.01 | 2026-06-29 |
| BIOCRYST PHARMACEUTICALS INC: Restructuring or exit costsOn June 25, 2026, the Board of Directors of BioCryst Pharmaceuticals, Inc. (the “Company”) approved a plan to discontinue the Company’s int... | 8-K2.05 | 2026-06-29 |
| The nominees for director were elected by the following votesThe Annual Meeting was held on June 11, 2026 for the purpose of (1) electing three directors to serve for a term ending at the Company’s 20... | 8-K5.07 | 2026-06-12 |
| Amended and Restated Stock Incentive Plan On June 11, 2026, at the 2026 Annual Meeting of Stock...Amended and Restated Stock Incentive Plan On June 11, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of BioCryst P... | 8-K5.02 | 2026-06-12 |
| The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as...The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein | 8-K7.01 | 2026-05-06 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.